Pharmafile Logo

What oncologists really want from booth strategy

August 19, 2025 | Congress, Inizio, oncology 

- PMLiVE

Simon Davenport, Global Head of Environments, Emota, an Inizio Engage company 

At this year’s ASCO® congress, the spotlight wasn’t just on science – it was on how the industry engages. Supporting over 30 clients and delivering 185 projects, Inizio witnessed the shift toward smarter, more sustainable congress environments.

Key takeaways included:

  • Oncologists want interactive learning: Engagement is moving beyond slides, with responsive booths, interactive LED walls, and digital-first experiences extending conversations well past the industry’s six-minute average.

  • Smart spaces are here to stay: With heat mapping, AI-powered personalization, and real-time content optimization, booths are evolving into dynamic, intelligent environments that adapt to audience needs.

  • Sustainability as strategy: Inizio’s circularity-first booth design delivered a 70% CO₂e reduction, 70.7% recyclability, and major cost savings – results that earned industry-leading awards and set a benchmark for measurable impact.

In a crowded oncology market, strategy-led storytelling, analytics-driven design, and sustainability-centered innovation are becoming essential to cut through the noise. The future of congress engagement will be intentional, data-informed, and deeply aligned with healthcare professionals’ learning preferences.

Read Simon’s full article here, or explore more in Inizio’s on-demand webinar Beyond the booth: Big ideas, smart spaces & strategic insights from ASCO® 2025.

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

AI in the clinic: How AI is reshaping clinical behavior

AI is becoming an increasingly important part of clinical practice, moving beyond administrative tasks to influence how physicians access information and make treatment decisions.

Oncology innovation: The human cost of keeping pace with advances in cancer care

New research from Inizio Evoke explores the growing complexity of oncology innovation and how pharmaceutical companies can better support healthcare professionals (HCPs).

AI-enabled biotech commercialization for a successful US therapy launch with Tonix

Inizio helped Tonix successfully launch the first FDA-approved therapy in its class in almost two decades by delivering an integrated, AI-enabled commercialization program spanning analytics, field operations, and launch readiness.

How pharma companies can use AI to scale personalized engagement without increasing complexity

AI is creating a world of opportunities for pharma companies to deliver more personalized HCP and patient engagement. But realizing the full potential of AI takes more than just introducing…

Creating the conditions for product launch success in a time of volatility

Volatility is reshaping the conditions for successful product launches. Market dynamics can shift quickly, assumptions can change, and teams are increasingly expected to make confident decisions in response.

Navigating uncertainty in life sciences

The life sciences industry is changing fast. Advances in AI, increasingly complex science, shifting market dynamics and evolving patient needs are creating new challenges for organizations developing and commercializing treatments….

Inizio appoints Oisín Ó Gógáin as Chief People Officer

Inizio has appointed Oisín Ó Gógáin as Chief People Officer.

Pharma leadership strategies for talent, AI adoption, and continuous learning

In a recent interview with Pharma Exec, Elaine Ferguson, Global President of Inizio Medical, explores how pharma leadership can support talent development, use AI to augment the workforce, encourage continuous…

Smarter science, sharper strategy: Expert insights from ASCO® 2026

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

Intelligent Commercialization™ across the pharma lifecycle

Pharma teams are under growing pressure to navigate launch complexity, identify risks earlier, and engage HCPs more effectively.